Letrozole — Dosing, Cycles, Half-Life & Side Effects

Letrozole is an aromatase inhibitor with a half-life of 2-4 days. Potent aromatase inhibitor for severe estrogen control. This page is educational harm-reduction reference compiled from peer-reviewed literature — not medical advice, not an endorsement, not a recommendation to use. Consult a licensed clinician before any decision.

IMPORTANT DISCLAIMER – NO DOCTOR-PATIENT RELATIONSHIP

Use of this Service, including any AI-generated responses, cycle recommendations, lab result analysis, risk assessments, or shared user content, does not create a doctor-patient, therapist-patient, or any other professional-client relationship. The information provided is for educational, informational, and harm-reduction purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment from a licensed physician. Never disregard professional medical advice or delay in seeking it because of something you have read or generated on this platform. If you have a medical emergency, call 911 (US) or your local emergency number immediately. Always consult your physician or other qualified healthcare provider with any questions regarding your health, medications, or cycle protocols. The operators of this platform are not licensed medical professionals and do not practice medicine.

Quick Facts

Class	Aromatase Inhibitors
Half-life	2-4 days
Detection window	21 days
Hepatotoxicity	Low
Suppression	0/10
Administration	oral
US regulatory status	fda-approved

Typical Dosing Ranges

Common dose range: On-cycle: 0.25-0.5mg E3D or EOD (Endocrine Society 2018, PMID: 29562364). Gyno-reversal rescue: 0.5-1mg/day short-course. Do NOT use 2.5mg/day on-cycle — that is the FDA-labelled breast-cancer dose and will ablate estradiol in men on testosterone.

Cycle length: As needed

Time to steady state: ~10 days

Clinical (FDA-labelled): 2.5mg/day — FDA-labelled adjuvant breast-cancer dose for postmenopausal women. Not an on-cycle reference for men.

On-cycle (community-reported): 0.25-0.5mg EOD or E3D — community-standard estradiol management

Rescue / acute management: 0.5-1mg/day short-course for active gynecomastia reversal. Re-test estradiol weekly. Discontinue when symptoms resolve.

Letrozole is the most potent of the third-generation AIs (~98% estradiol suppression at full dose). Male PED use is at sub-clinical doses an order of magnitude below the BC label.

Dose ranges are compiled from published pharmacokinetic studies and community-reported usage. Where a value is community-reported rather than clinically studied, this page and its structured data flag it. Lower end of any range is always the safer starting point.

Stacking Considerations

No structural stacking blockers. Standard harm-reduction rules apply: minimize total androgen load, minimize oral exposure, and monitor bloodwork.

PCT Requirements

Depot clearance estimate: ~10 days post-last-dose before SERM start (5 × apparent depot half-life of 48h).
Never stack two SERMs. Extend a single SERM (tamoxifen OR enclomiphene/clomiphene) rather than combining.
Use the cycle planner to generate a full protocol based on your complete stack, not this compound alone.

Side Effect Profile

Easy to crash estradiol — joint pain, lipid disruption, libido loss
Joint pain at therapeutic doses
Expensive
Limited availability

Known Interactions

Testosterone Cypionate + Letrozole
minor — pharmacokinetic
Letrozole is potent AI. Over-suppression of estrogen is possible.
Recommendation: Start with very low doses. Monitor E2 closely to avoid crash.
Monitor: Estradiol, Joint pain, Mood

Monitoring (Bloodwork & Vitals)

Comprehensive metabolic panel (baseline, mid-cycle, post-cycle)
Lipid panel (total cholesterol, HDL, LDL, triglycerides)
CBC (hemoglobin, hematocrit — watch for erythrocytosis)
Sex-hormone panel (Total T, Free T, Estradiol sensitive, SHBG, LH, FSH)
Blood pressure (weekly self-check; flag systolic >140 or diastolic >90)

Baseline bloodwork is recommended before any cycle. Discontinue if liver enzymes exceed 3× upper limit of normal or if hematocrit exceeds 54%.

Frequently Asked Questions

What is the half-life of Letrozole?

Letrozole has a half-life of approximately 2-4 days. Clearance estimate: 48h × 5 = 240h = 10 days. This figure is used to determine injection frequency (for esters) and post-cycle clearance timing.

What is the typical dose range for Letrozole?

Commonly reported ranges for Letrozole: On-cycle: 0.25-0.5mg E3D or EOD (Endocrine Society 2018, PMID: 29562364). Gyno-reversal rescue: 0.5-1mg/day short-course. Do NOT use 2.5mg/day on-cycle — that is the FDA-labelled breast-cancer dose and will ablate estradiol in men on testosterone.. Cycle length: As needed. These are compiled from published studies and community-reported usage — individual response varies and lower end is always preferred.

Does Letrozole suppress natural testosterone?

Letrozole causes minimal suppression of the HPTA axis (score 0/10). PCT may still be advisable depending on stack and duration.

Is Letrozole liver toxic?

Hepatotoxicity rating: Low. Non-17αα compound — liver stress is lower but still warrants periodic monitoring during a cycle.

What is Letrozole typically used for?

Letrozole is commonly used for: Severe estrogen control, Gynecomastia reversal (short-course only), Advanced users. Intended-use context does not imply safety — every use case carries the same underlying pharmacological risks.

Citations

Disclaimer

StackItSmart is an independent harm-reduction reference. The content above is compiled from peer-reviewed literature and is not medical advice, not an endorsement, and not a recommendation to use Letrozole. Performance-enhancing compounds carry legal, endocrine, cardiovascular, and hepatic risks. Consult a licensed clinician before any decision. StackItSmart does not provide sourcing, procurement, or dosing prescriptions.